The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2024 | The emerging role of immunotherapy for microsatellite stable colorectal cancer
Juan Manuel O’Connor, MD, MSc, Instituto Alexander Fleming, Buenos Aires, Argentina, provides insights into the role of immuno-oncology in treating microsatellite-stable (MSS) colorectal cancer (CRC). There is significant research currently focused on characterizing the microbiome in patients with MSS CRC, as well as recent data on the promising efficacies of botensilimab and balstilimab. For non-MSS CRC, it is believed to be that understanding the role of immunotherapy in treating proficient tumors is critical in the future. This interview took place at 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancer Annual Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
